Salesforce, Unity see their stocks fall after Piper Sandler abandons bullish stance
Shares of Salesforce Inc. (CRM) and Unity Software Inc. (U) were falling Monday after Piper Sandler analyst Brent Bracelin downgraded the stocks to neutral from overweight. His downgrade of Salesforce comes as he sees growing risk around execution and mergers, "AI monetization uncertainty," and a more balanced risk-reward profile following a 50%-plus rise in the shares so far this year. Salesforce shares were off 1.6% in morning activity Monday. Bracelin also moved to a neutral stance on Unity, whose shares were off 2.5% early Monday, citing "potential downside risks to 2024 ad growth after the pricing spat with game developers." He downgraded shares of Asana Inc. (ASAN) and Alteryx Inc. (AYX) to underweight from neutral, while lowering his rating on Matterport Inc. (MTTR) to neutral from overweight. "Despite taking a more cautious [software] stance into year-end on this mismatch on 2024 expectations," his highest-conviction picks are Microsoft Corp. (MSFT) among large-capitalization names and Procore Technologies Inc. (PCOR) among small caps.
-Emily Bary
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-23-23 1011ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks